化学信息：
| 化学名 | 5-(benzylideneamino)-6-[(E)-benzylideneamino]-2-sulfanylidene-1H-pyrimidin-4-one |
|
| 简称 | SCR7 | |
| 别名 |
CS-3903, AK174235, BC600700, QC-11823, X3557 |
|
| 中文名 | N/A | |
| 化学式 | C18H14N4OS | |
| 分子量 | 334.4 | |
| CAS号 | 1533426-72-0 | |
| 纯度 | 98% | |
| 溶剂/溶解度 |
Water<1mg/ml; DMSO45mg/ml; Ethanol<1mg/ml |
|
| 溶液配制 | 5mg加入1.5ml DMSO，或者每3.34mg加入1ml DMSO，配制成10mM溶液。SF1136-10mM用DMSO配制。 |
生物信息：
| 产品描述 | SCR7 is a molecule that inhibits joining of DSBs in cell-free repair system; inhibits NHEJ (nonhomologous end-joining) in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. | ||||
| 信号通路 | Others | ||||
| 靶点 | Ligase IV inhibitor | NHEJ inhibitor | － | － | － |
| IC50 | ~40nM | ~40nM | － | － | － |
| 体外研究 | SCR7 does not induce DSBs directly to the genome and is Ligase IV dependent. Besides, upon incubation of oligomeric dsDNA or supercoiled plasmid DNA with increasing concentrations of SCR7, there was no evidence for DNA breaks. Accumulation of DSBs leads to cell death upon SCR7 treatment with a dose-dependent decrease in cell proliferation of MCF7, A549, and HeLa with an IC50 of 40, 34 and 44μM, respectively, which was further confirmed by DIC imaging in MCF7. T47D, A2780 and HT1080 were also sensitive to SCR7, with an IC50 of 8.5, 120, and 10μM, respectively. SCR7 encapsulated micelles (ES) were also characterized by small-angle neutron scattering (SANS). Encapsulated SCR7 treatment resulted in accumulation of DNA breaks within the cells, resulting in cell cycle arrest at G1 phase and activation of apoptosis. | ||||
| 体内研究 | SCR7 treatment (10mg/kg, six doses) significantly reduced breast adenocarcinoma-induced tumor in mice. Untreated tumor animals survived only for 52 days, whereas treated animals exhibited ～4-fold increase in lifespan. Treatment with SCR7 resulted in regression of tumors with no obvious adverse effects. In addition, HPLC analysis of serum following administration of SCR7 into mice (20mg/kg) showed bioavailability of 114μg/ml and a t1/2 of 1hr. | ||||
| 临床实验 | N/A | ||||
| 特征 | N/A | ||||
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
| 酶活性检测实验 | |
| 方法 | N/A |
| 细胞实验 | |
| 细胞系 | N/A |
| 浓度 | N/A |
| 处理时间 | N/A |
| 方法 | N/A |
| 动物实验 | |
| 动物模型 | N/A |
| 配制 | N/A |
| 剂量 | N/A |
| 给药方式 | N/A |
| 产品编号 | 产品名称 | 包装 |
| SF1136-10mM | SCR7 (DNA ligase IV抑制剂) | 10mM×0.2ml |
| SF1136-5mg | SCR7 (DNA ligase IV抑制剂) | 5mg |
| SF1136-25mg | SCR7 (DNA ligase IV抑制剂) | 25mg |
| — | 说明书 | 1份 |
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
